2016 ACR/ARHP Annual Meeting

November 11-16, 2016. Washington, DC.

View by Number View by Title View Sessions

View by Date

Sunday, November 13, 2016

9:00AM-11:00AM: Abstract Number: 21

Outcomes of Rheumatoid Arthritis Patients with Hip Fracture

Epidemiology and Public Health - Poster I

9:00AM-11:00AM: Abstract Number: 798

Oxidized Phospholipids,Lipoprotein(a) and Glycosphingolipid Associated B-1,4 Galactosyltransferase in a Johns Hopkins Cohort of Patients with Systemic Lupus Erythematosus

Systemic Lupus Erythematosus – Clinical Aspects and Treatment - Poster I: Clinical Trial Design and Current Therapies

9:00AM-11:00AM: Abstract Number: 377

Pain and Quality of Life Profiles in Colombian Patients with Rheumatoid Arthritis: A Mixed Cluster Analysis

Pain – Basic and Clinical Aspects - Poster

9:00AM-11:00AM: Abstract Number: 379

Pain Catastrophizing Decreases in RA Patients Starting, Adding or Switching a DMARD

Pain – Clinical Aspects - ARHP Poster

9:00AM-11:00AM: Abstract Number: 685

Paradoxical Psoriasis Secondary to Anti-Tnfa Agents in Patients with Ankylosing Spondylitis: A Nationwide Population-Based Cohort Study

Spondylarthropathies and Psoriatic Arthritis – Clinical Aspects and Treatment - Poster I: Axial and Peripheral Spondyloarthritis – Clinical Aspects, Imaging and Treatment

9:00AM-11:00AM: Abstract Number: 740

Patient Adherence with Mycophenolate Mofetil Therapy in a Systemic Lupus Erythematosus Cohort: A Multi-Factorial Assessment

Systemic Lupus Erythematosus – Clinical Aspects and Treatment - Poster I: Clinical Trial Design and Current Therapies

9:00AM-11:00AM: Abstract Number: 110

Patient Decisions Related to Hip and Knee Arthroplasty and the Factors Influencing Them

Health Services Research - ARHP Poster

9:00AM-11:00AM: Abstract Number: 456

Patient Engagement in Research: Understanding Patient Interest and Needs

Quality Measures and Quality of Care - ARHP Poster

9:00AM-11:00AM: Abstract Number: 541

Patient Goals in Rheumatoid Arthritis Care: A Literature Review

Rheumatoid Arthritis – Clinical Aspects - Poster I: Clinical Characteristics/Presentation/Prognosis

9:00AM-11:00AM: Abstract Number: 224

Patient Perception of Gout Flares As a Measure of Outcome: Results from an International Study

Metabolic and Crystal Arthropathies - Poster I: Clinical Practice

9:00AM-11:00AM: Abstract Number: 106

Patient Satisfaction Survey of a Newly Set up Physiotherapist Lead Axial Spondyloarthritis Clinic

Health Services Research - ARHP Poster

9:00AM-11:00AM: Abstract Number: 100

Patient Support Program for Adalimumab-Treated Patients in Brazil: Impact on Patients’ Adherence and Persistence

Health Services Research - Poster I

9:00AM-11:00AM: Abstract Number: 88

Patient-Clinician Co-Participation in Design of an App for RA Management Via Telehealth Yields an App with High Usability and Acceptance

Health Services Research - Poster I

9:00AM-11:00AM: Abstract Number: 522

Patient-Provider Discordance in Global Assessments of Disease Activity in Patients with Rheumatoid Arthritis: Persistence, Predictors and Impact

Rheumatoid Arthritis – Clinical Aspects - Poster I: Clinical Characteristics/Presentation/Prognosis

9:00AM-11:00AM: Abstract Number: 591

Patient-Reported Outcomes for Etanercept Therapy in Adult Patients with Moderate to Severe Rheumatoid Arthritis Who Failed Adalimumab Treatment

Rheumatoid Arthritis – Small Molecules, Biologics and Gene Therapy - Poster I

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].